BioCurex, Inc.(fka BOCX)

[HALF FULL GLASS]

In-vitro experiments show 100% killing in a variety of cancers with 5-15% death of normal cells.

I THOUGHT THIS MAY BE HELPFUL....100% IS PRETTY GOOD IN MY BOOK!THIS IS A REPRINT.
RECAF - A New Tumor Marker
Ricardo Moro
BioCurex Inc. Vancouver, Canada ([e-mail]).
The receptor for AFP (RECAF) is used to incorporate fatty acids and other molecules carried by AFP into fetal
cells from most organs and tissues. RECAF is not expressed by normal adult cells but it reappears in cancer
cells thus acting as a broad spectrum oncofetal antigen. The AFP binding site on RECAF is the glycan portion
of several soluble and membrane glycoproteins. Antibodies against the RECAF glycan can be used for detecting
cancer cells by immuno-histology on paraffin or frozen tissue sections, as well as for immuno-cytology on
smears.
We have also developed a RIA to detect RECAF in serum and we have obtained high sensitivity values (with
95% specificity) for the following cancers: Breast (93%), cervical (86%), colorectal (75%), leukemia and
lymphomas (80%), lung (94%), melanoma (80%), ovarian (96%), prostate (88%) and stomach (90%). Most
benign lesions of the prostate (BPH) or the breast have serum RECAF values similar to those of normal
individuals thus offering very good discrimination between benign tumors and malignancy.
Anti-RECAF antibodies or AFP itself can also be used for targeting cancer cells with radioactivity for tumor
imaging and with mercurial compounds to selectively kill cancer cells. In-vitro experiments show 100% killing
in a variety of cancers with 5-15% death of normal cells. The implications for cancer therapy and management
are discussed.
0-57 New markers
http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowPDF&ProduktNr=224124&Ausgabe=23...